Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,840 across all filing types
Latest filing 2026-03-10 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
普洛药业股份有限公司2026年股票期权激励计划（草案）摘要
Board/Management Information Classification · 95% confidence The document is a detailed summary of a 2026 stock option incentive plan (draft) for 普洛药业股份有限公司. It includes extensive information about the stock option plan's purpose, legal basis, management, scope, stock option quantities, pricing, conditions for granting and exercising options, performance targets, adjustment methods, and governance. The document references relevant laws and regulatory bodies such as the China Securities Regulatory Commission and Shenzhen Stock Exchange. It is a comprehensive plan document, not a brief announcement or a simple notice. It does not contain financial statements or earnings data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, audit report, or legal proceeding report. It is not a remuneration report or a proxy statement. The content is focused on management and governance of stock option incentives, which is a form of management information related to executive compensation and corporate governance. Given the detailed nature and focus on management and board-level decisions regarding stock option incentives, the best fitting category is Board/Management Information (MANG).
2026-03-10 Chinese
普洛药业股份有限公司第二期员工持股计划管理办法
Regulatory Filings Classification · 95% confidence The document is a detailed management plan for the company's second employee stock ownership plan (员工持股计划管理办法). It includes comprehensive information about the plan's purpose, principles, participants, stock sources, pricing, lock-up periods, performance assessments, rights, procedures, changes, termination, and distribution of rights. The content is regulatory and procedural in nature, focusing on the governance and operational rules of the employee stock ownership plan rather than financial results, earnings, or capital raising. It is not an announcement of a report but a substantive document outlining the management and operation of an employee stock ownership plan. This type of document fits best under the category of Regulatory Filings (RNS), as it is a compliance and governance-related filing that does not fall into other more specific categories like capital updates, earnings releases, or management changes.
2026-03-10 Chinese
股票期权激励计划自查表
Governance Information Classification · 95% confidence The document is a detailed self-inspection checklist related to a 2026 equity incentive plan of 普洛药业股份有限公司. It includes compliance checks, disclosures about stock options, performance metrics, legal opinions, and procedural adherence. The content focuses on the equity incentive plan's structure, compliance, and governance rather than financial results or earnings. It is not an announcement, transcript, or report of financial performance but a compliance and governance-related document specific to equity incentives. This fits best under the category of Governance Information (CGR), which covers internal rules, board structure, and governance practices, including equity incentive plans.
2026-03-10 Chinese
北京市康达律师事务所关于普洛药业股份有限公司第二期员工持股计划的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's second employee stock ownership plan. It extensively discusses the legal compliance, procedures, and qualifications related to the employee stock ownership plan, referencing relevant laws and regulatory guidelines. It is not a financial report, earnings release, or management discussion. It is a standalone legal opinion document related to a specific corporate action (employee stock ownership plan). This type of document fits best under the category of Regulatory Filings (RNS), as it is a compliance/legal document that does not fit into other more specific categories like MANG or CAP. The document length (6672 characters) and content confirm it is not a brief announcement or a report publication announcement. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2026-03-10 Chinese
关于对下属公司担保的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding the progress of guarantees provided to its subsidiaries. It details specific guarantee agreements, amounts, terms, and the financial status of the guaranteed subsidiaries. The document includes board opinions and cumulative guarantee amounts. It is a formal disclosure about the company's guarantee activities rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but focuses on guarantee-related information. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about guarantees and does not match other more specific categories like Annual Report, Interim Report, or Capital/Financing Update. The document length is 2372 characters, which is relatively short and typical for an announcement rather than a full report.
2026-02-27 Chinese
关于对下属公司担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding the progress of guarantees provided to its subsidiaries. It details specific guarantee contracts, amounts, terms, and the financial status of the guaranteed subsidiaries. The document includes information about board approval and cumulative guarantee amounts. There is no indication that this is a full financial report, audit report, or earnings release. It is a regulatory announcement about financing guarantees, which fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided by the company. The document length is about 4983 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2026-01-30 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.